Background: Neoadjuvant treatment of locally advanced disease with BRAFinhibitors is expected to increase the likelihood of a R0 resection. We present 6 patients with stage III unresectable melanoma, neoadjuvantly treated with BRAFinhibitors.
Introduction:
For stage III melanoma patients, 5-year overall survival is associated with tumor burden and ranges between 30 and 80%. 1 It is well established that a radical resection of stage III melanoma is prognostically favorable compared to a R1 resection. In some cases, a R0 resection is not possible due to tumor size and/ or adherent vital structures such as neurovascular bundles impeding radical surgical treatment. In cases where stage III melanoma is deemed unresectable, patients are historically treated in a similar fashion to stage IV patients. Since the introduction of targeted therapy and immune checkpoint inhibitors, the prognosis for patients with unresectable stage III and stage IV melanoma have improved. [2] [3] [4] [5] [6] Approximately 50% of cutaneous melanomas harbor a BRAF-mutation. 7 These patients can be treated with a BRAF inhibitor, alone or in combination with a MEK-inhibitor. This results in exceptionally fast and extensive responses in approximately 50% of patients, within 6 weeks. 3, 8, 9 Median response duration for vemurafenib is 6.7 months and 5.1 months for patients receiving dabrafenib. 8, 9 The addition of a MEK inhibitor prolongs progression free survival to a median of 9.3 months. 4 Using BRAF-inhibitors as an induction treatment to reduce tumor size in unresectable stage III melanoma, paving the way for a radical surgical resection, is a logical next step. We present data on six unresectable stage III melanoma patients treated with BRAF inhibition neoadjuvantly in order to facilitate a surgical resection, at our center. To determine the response to BRAF inhibitor treatment, a grading system was created. The aim of this study was to describe the feasibility and pitfalls of this treatment approach.
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Materials and Methods:

Study population
The population consisted of patients with locally advanced stage III melanoma that was deemed either unresectable due to encasement of adherent structures such as arteries, veins or nerves, or due to the mutilating nature of a resection. This study was conducted at the University Medical Center Groningen (UMCG). This is a university hospital and tertiary referral center in the Northern part of the Netherlands with a catchment area of 1.5 million inhabitants. Patients were included between 2012 and 2015. All patients tested positive for a therapy responsive BRAF mutation and had no history of prior BRAF-inhibitor treatment. Locally advanced stage III melanoma was deemed unresectable based on clinical and/or radiological evaluation and after discussion during a multidisciplinary tumor board meeting. This multidisciplinary panel consisted of at least one surgical oncologist, radiologist (or nuclear medicine physician), medical oncologist, radiotherapist, dermatologist, pathologist and a neurologist. In all patients a fluorine-18 fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) combined with a diagnostic contrast-enhanced CT scan of thorax and abdomen was performed, to exclude stage IV melanoma prior to start BRAF-inhibitor treatment.
Study design
After medical evaluation and informed consent to the treatment plan, BRAF inhibitor treatment was commenced. Patients were treated with BRAF-inhibition and, based on availability, combined with MEK inhibition. From mid-2015 onwards, combined dabrafenib and trametinib were available as standard of care.
Physical examination was performed at every outpatient clinic visit (every 2-4 weeks). Response evaluation by imaging was usually performed after two months of BRAF-inhibitor treatment. This interval was prolonged if it was clinically evident that surgical resection could not be performed at that time and BRAF-inhibitor treatment was tolerated well.
Preoperative BRAF inhibition in patients
Patients were treated until maximal response to BRAF-inhibitor treatment. Maximal response was reached if there was no longer evidence of diminishing tumor size either by clinical or radiological examination. Resection was planned within 6 weeks of maximum response. Postoperative morbidity and mortality were assessed during a 30-day follow-up period. R0 resection was defined as a complete resection with tumor-free resection margins. After the surgical resection, follow-up was conducted by the surgical oncologist every three months by physical examination, serum LDH and S-100B levels and imaging when indicated.
Outcomes
Data were collected concerning patient characteristics, treatment regimen and treatment duration. Toxicity of neo-adjuvant treatment was assessed at every outpatient clinic visit (every 2-4 weeks) and was retrospectively graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4·0 by evaluation of the electronic health records. 10 Histological sampling to determine BRAF mutation status was either performed on the primary tumor, or a metastasis.
After histological sampling, DNA extraction was performed using Cobas extractionkit, Roche©. BRAF-mutation analysis prior to September 2014 was performed using HRM-screening and confirmation with Sanger sequence analysis. After September 2014, multiplex PCR and PGM/Ion-Torrent sequence analysis containing the following genes: ALK, BRAF, EGFR, ERBB2, GNA11, GNAQ, KIT, KRAS, NRAS, PDGFRA en PIK3CA was performed. Pathology specimens were reviewed by a melanoma pathologist, in particular with respect to the estimated percentage of fibrosis with melanophages, necrosis and the percentage of vital tumor tissue in the specimen. A grading system for response to BRAF-inhibitor treatment was created based on the percentage of vital tumor tissue, fibrosis, melanophages and/or necrosis in the resected specimen (see Figure 1 ).
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Figure 1 Response grading system to BRAF-inhibitor treatment
Statistical analysis
Descriptive statistics were performed using IBM SPSS statistics, version 22.
Results:
Patient and tumor characteristics
Six patients were treated neoadjuvantly with BRAF inhibitors between January 2012 and December 2015. One patient presented with unresectable melanoma at the time of the primary diagnosis. The other five patients presented with unresectable local disease after treatment of the primary melanoma, with a median interval of 60 months (range 2-100, Figure 2 ). The patient and tumor characteristics and treatment regimen are shown in Table 1 Preoperative BRAF inhibition in patients Patient two suffered from grade III headache, for which she was admitted to the hospital.
All patients recovered completely after treatment discontinuation.
Surgical resection
Surgical resection was performed lege artis. Fibrosis of tumor tissue was frequently seen. This added technical difficulty to the procedure. However, this did not lead to surgical complications intraoperatively. A R0 resection was achieved in five patients.
Median postoperative hospital stay was six days (range 5-9). One patient was readmitted 15 days after discharge due to a retroperitoneal hematoma presenting with fever, abdominal pain, leukocytosis and hydronephrosis. The hematoma was caused by postoperative bleeding and was resolved by re-exploration; the patient recovered fully.
Another patient was readmitted five days after discharge with a wound infection. This resolved after intravenous administration of antibiotics and negative wound pressure therapy during six weeks. The 30-day postoperative period was uncomplicated in the remaining four patients.
Pathological evaluation
In one patient a complete pathological response was found, the five other resected specimens contained vital tumor tissue ( Table 3 ). The degree of response to BRAFinhibitor treatment varied throughout the different resected specimens within the patients (Figure 4 ). According to the grading system in Figure 1 .
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Discussion:
This study shows that preoperative BRAF inhibitor treatment of unresectable stage III melanoma is feasible. Toxicity was minimal and there were few postoperative complications attributable to the neo-adjuvant treatment.
In other tumor types, neo-adjuvant chemotherapy either as mono treatment or in combination with radiation is an established treatment option, and has proven to be valuable in achieving R0 resections and local control after surgical treatment. 11, 12 The desire for improved DFS and overall survival in melanoma patients has led to investigation of neo-adjuvant interferon and bevacuzimab in patients with high risk primarily resectable lymph node metastases. Clinical response was seen in approximately 50% of patients. 13, 14 No significant improvement of DFS nor overall survival was demonstrated in these studies. None of these studies have focused on unresectable stage III melanoma.
Case reports describing successful induction of tumor response with BRAF-inhibitors followed by a successful surgical resection in unresectable stage III melanoma are scarce. [15] [16] [17] [18] One previously published retrospective patient series describes 15 patients with locoregionally advanced, BRAF mutated, stage III melanoma. These patients were treated with BRAF inhibitors and six patients had a radical resection of residual disease.
None of these patients were treated intentionally in a neo-adjuvant fashion. Pathologic responses seen in the resected specimens were comparable to those in our series. The objective response rate was, however, lower, with only 6 out of 15 patients receiving Preoperative BRAF inhibition in patients surgical resection following BRAF-inhibitor treatment. 19 Side effects due to BRAF inhibitor treatment in our series were comparable to results described in the literature. 3, 9 In this series BRAF-inhibitor treatment led to fibrosis of tumor tissue and added a challenge to the surgical procedure itself, however it did not lead to intra-operative complications in our series. This is compatible with previous reports which do not describe increased postoperative complications after BRAF-inhibitor treatment. 19, 20 The use of BRAF inhibitors as a single therapy (or combined with a MEK inhibitor) in stage IV and unresectable stage III melanoma is standard of care. When melanomas harbor a therapy responsive BRAF mutation, treatment with BRAF inhibitors leads to objective rapid and impressive responses in 53% of patients treated with vemurafenib and 50% of patients treated with dabrafenib. In a small subset of patients (~20%) durable responses of >2 years on the BRAF and MEK inhibitors combination have been described. 21 The possibility of long term survival on BRAF inhibitor treatment, complicates decisions on timing of surgical procedures after neo-adjuvant BRAF-inhibitor treatment. This is illustrated by patients three and five who were treated for more than two months before surgical resection of locally advanced stage III melanoma was planned ( Figure 2) . A risk of this long term BRAF-inhibitor treatment, is the possibility of disease progression and the concurrent loss of a surgical window during BRAF-inhibitor treatment. This may be preventable by frequent response evaluation. Due to the fast responses seen with BRAFinhibitor treatment, a surgical resection can be planned after only weeks of response to BRAF-inhibitor treatment, therefore the treatment period can be relatively short.
The risk of disease progression during the first six weeks of treatment is approximately three percent. [22] [23] [24] Adequate timing of the surgical procedure is of great importance, this remains a challenging and multidisciplinary decision. The differences in treatment duration in this patient series underlines this challenge.
Pathological responses to BRAF-inhibitor treatment varied throughout all the resected specimens within the patients in this study. Therefore, existing grading systems for neo-adjuvant chemotherapy for instance as in breast carcinomas were not applicable, as responses to chemotherapy in breast carcinomas are more similar throughout the resected specimens within the patients. 25 In future neo-adjuvant trials, grading systems should describe the percentage of vital tumor tissue throughout the resected specimen.
Mixed responses were frequently seen in this study and should be described in future trials.
In this series three out of six patients had a recurrence of which two were local recurrences. Adjuvant radiation therapy decreases the risk of local recurrences after lymph node dissection compared to observation in high risk stage III melanoma patients (21 % relapse VS 36% relapse) and can also be considered in this patient group. 26 In the future, neo-adjuvant treatment followed by resection of advanced stage III melanoma could potentially be followed adjuvant immunotherapy. The use of adjuvant ipilimumab improves 3-year recurrence-free survival in complete resected stage III melanoma patients compared to adjuvant placebo (46·5% VS 34·8%). 27, 28 There are several studies for neo-adjuvant treatment of resectable stage III melanoma ongoing at this moment (ClinicalTrials.gov identifiers: NCT01972347, NCT02036086, NCT02858921, NCT02303951, Trialregister.nl identifier: NTR4654). These prospective studies will give more insight into response rates and probability of achieving R0 resections. In current and future clinical trials, a definite neoadjuvant treatment period is needed and should be defined, to help determine reproducibility and clinical applicability of data, as well as longer follow-up in larger populations to be able to truly assess long-term clinical benefit.
Conclusion:
This experience with pre-operative BRAF-inhibitor treatment shows that this treatment is feasible in unresectable stage III melanoma patients. It can lead to resectable stage III melanoma and facilitate a R0 resection in previously unresectable patients. Future research should be aimed at determining which patients benefit form neo-adjuvant and adjuvant treatment. In order to be able to determine in which patients treatment benefits outweigh treatment morbidity.
